Podcasts about venereology

In this episode, Dr. Sarah Walsh sits down with Prof. Branka Marinović, the newly appointed President of the European Academy of Dermatology and Venereology. Prof. Marinović, who also serves as the president of the Croatian Dermatological Society and Head of the University Department of Dermatology in Zagreb, shares her remarkable journey in dermatology, her vision for advancing dermatology education and her advice for young professionals. Join them to get to know more about a leader at the forefront of dermatology... and even to discover some tips for visiting Zagreb!   Link to video version: https://www.youtube.com/playlist?list=PL2DbuyADMP5mFx4sZqS_vQtdTGOGIbwb1   You are invited to participate in our survey to improve the show. Your feedback is valued and appreciated to allow us to better serve our audience: https://eadv.org/eadv-podcast-survey/  

In this episode, Prof. Murrell, Head of the Dermatology Department at the St George Hospital, with an academic appointment at the NSW (Sydney, Australia) and several academic appointments in Europe, UK, USA, delves into the fascinating world of autoimmune blistering diseases, joined by her guest, Ailin He, a medical student who recently published ground-breaking research in the Journal of Dermatology and Venereology (JEADV). In their article, Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid-induced myopathy, they present a multi-country study involving 139 patients, revealing the prevalence, risk factors, and recovery patterns of this condition. Together, the two speakers explore steroid-induced myopathy, a complication of prolonged glucocorticoid use often overlooked in dermatology. Tune in to learn about the innovative Glucocorticoid Toxicity Index (GTI), the impact of cumulative steroid doses, and strategies to improve patient outcomes and offering a hopeful outlook for managing complex autoimmune conditions. Find the link to the article here: https://onlinelibrary.wiley.com/doi/10.1111/jdv.20149 Don't miss out!   Link to video version: https://www.youtube.com/playlist?list=PL2DbuyADMP5mFx4sZqS_vQtdTGOGIbwb1   You are invited to participate in our survey to improve the show. Your feedback is valued and appreciated to allow us to better serve our audience: https://eadv.org/eadv-podcast-survey/  

Welcome to the latest episode of the Evidence-Based Hair Podcast, hosted by Dr. Jeff Donovan, dermatologist and hair loss specialist. In this episode, Dr. Donovan delves into a fascinating study published in the Journal of the American Academy of Dermatology and Venereology, which explores the potential association between hair loss and the use of popular weight loss medications, such as semaglutide and terzepatide. Dr. Donovan discusses the methodology and findings of the study, which utilized the FDA Adverse Event Reporting System to analyze reports of alopecia linked to these drugs. The episode highlights the importance of post-marketing research in uncovering side effects not initially apparent in clinical trials. Join Dr. Donovan as he explains the statistical technique of disproportionality analysis used in the study, and its implications for understanding the potential hair loss risks associated with these medications. The episode also emphasizes the need for further research to better understand the timing, mechanism, and prevalence of hair loss among different patient groups. Stay tuned for next week's episode, where Dr. Donovan will explore the effects of metformin on central centrifugal cicatricial alopecia, based on a recent study in JAMA Dermatology. Thank you for tuning in and supporting the Evidence-Based Hair Podcast, dedicated to advancing education and research in the complex world of hair loss.   STUDIES REFERENCED IN THIS EPISODE   Hannah Godfrey, Zachary Leibovit-Reiben, Patrick Jedlowski, Rebecca Thiede. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol . 2024 Jun 24. doi: 10.1111/jdv.20197. Online ahead of print.

En junio y julio del 2024, estamos transmitiendo algunos de nuestros episodios más escuchados durante la tercera temporada. Reanudaremos con nuestra cuarta temporada en agosto del 2024. Muchas gracias a todos nuestros oyentes por su apoyo y por compartir nuestros episodios de "Pediatras en Línea". Este episodio tiene un invitado de lujo desde Madrid, España, el Dr. Antonio Torrelo.  Una eminencia en Dermatología Pediátrica como clínico, investigador, educador y mentor de muchas generaciones de Dermatólogos Pediatras en Europa y a nivel mundial.   El Dr. Antonio Torrelo es graduado en medicina desde 1988 y especialista en dermatología desde 1992. Realizó su especialidad en el Hospital Ramón y Cajal de Madrid. Desde 1992 es médico dermatólogo en el Servicio de Dermatología del Hospital Infantil del Niño Jesús de Madrid, y desde 2007 es Jefe de dicho servicio.  El Dr. Torrelo ja sido presidente del Grupo Español de Dermatología Pediátrica (2001-2004), de la European Society of Pediatric Dermatology (2017-2019) y de la International Society of Pediatric Dermatology (ISPD) (2013-2017). Fue presidente del Congreso Mundial de Dermatología Pediátrica en Madrid, 2013.  El Dr. Torrelo se desempeñó como Editor en Jefe de Actas Dermosifiliográficas (2002 a 2006) y Editor Asociado de Pediatric Dermatology (2007-2021). Pertenece al Comité Editorial del Journal of the American Academy of Dermatology (2010 a 2013 y 2018-presente). Actualmente es Editor en Jefe de la revista JEADV Clinical Practice.  El Dr. Torrelo ha actuado como editor asociado de Schachner LA, Hansen RC. Textbook of Pediatric Dermatology, 4ª edición; Editor principal de Schachner LA, Hansen RC. Textbook of Pediatric Dermatology, 5ª edición, 2023; Editor asociado de Bolognia J, Schaffer JV, Cerroni L. Dermatology, 4ª edición y 5ª edición (en preparación). También ha escrito o es coautor de más de 30 capítulos en libros de texto internacionales.  El Dr. Torrelo ha dictado conferencias en los congresos de la European Academy of Dermatology and Venereology (1993-2019), la European Society of Pediatric Dermatology (2002-2020), el Congreso Mundial de Dermatología Pediátrica (2001-2021) y en centenas de congresos y cursos internacionales adicionales, incluida la Society for Pediatric Dermatology (EE. UU.) en 2010 (The Esterly Lecture), 2011 (The Founders Lecture) y en 2021.  El Dr. Torrelo es autor o coautor de más de 330 artículos científicos en revistas indexadas en PubMed.  ¿Tienes algún comentario sobre este episodio o sugerencias de temas para un futuro podcast? Escríbenos a pediatrasenlinea@childrenscolorado.org.

Welcome to another episode of the Evidence-Based Hair Podcast. In this episode, Dr. Donovan delves into an insightful study by Zhao and colleagues, published in the Journal of the European Academy of Dermatology and Venereology, titled "Baricitinib Therapy for Pediatric Patients with Severe Alopecia Areata." This episode continues the June series dedicated to JAK inhibitors. Dr. Donovan highlights the increasing global use of these medications for treating severe alopecia areata, including the recent approvals of baricitinib and ritlicitinib. The featured study examines the effectiveness and safety of baricitinib in treating children with severe alopecia areata, focusing on a small group of 10 patients aged between under two years to 13 years. The results reveal promising regrowth and mild side effects, underscoring the potential of baricitinib for younger patients. Dr. Donovan discusses the broader implications of these findings, including the likelihood of future approvals for younger age groups and the importance of long-term safety data. He emphasizes the need for ongoing research and real-world studies to better understand the prolonged effects of JAK inhibitors. Join Dr. Donovan next week for the final episode of the June series, where he will explore a study on the use of topical tofacitinib for treating lichen planopilaris and frontal fibrosing alopecia.

In this episode of the Venereology Talks series, Anastasia Abaitancei a third-year resident, interviews Professor Mihael Skerlev about HPV vaccinations. The conversation delves into trends and contributing factors in the spread of HPV infections, emphasizing the need for education and awareness among patients and healthcare providers. Professor Skerlev also shares insights on training young doctors and creating a safe space for patients to discuss sensitive topics. The episode concludes with a discussion on the future of HPV research and the importance of international collaboration in addressing research gaps. Tune in to learn more about the challenges and opportunities in HPV prevention and treatment.   Link to video version: https://www.youtube.com/playlist?list=PL2DbuyADMP5mFx4sZqS_vQtdTGOGIbwb1   You are invited to participate in our survey to improve the show. Your feedback is valued and appreciated to allow us to better serve our audience: https://eadv.org/eadv-podcast-survey/

आमिर खान के साथ फिल्म दंगल में काम कर चुकी सुहानी भटनागर की महज़ 19 साल की उम्र में अचानक हुई मौत से सभी सदमे में हैं.  सभी यह जानकर हैरान है की सुहानी की मौत स्किन से जुड़ी किसी बीमारी से हुई है. हर किसी के जहन में बस एक ही सवाल उठ रहा है कि आखिर ऐसी कौन सी बीमारी है जिसने इतनी कम उम्र में ही सुहानी की जान ले ली. जानिए आज ABP LIVE Podcasts पर FYI में जहाँ हमारे साथ जुड़ी हैं Dr Seema Oberoi Lall, MBBS, MD - Dermatology, Venereology & Leprosy, C.K. Birla Hospital, Gurgaon

In this episode of the Venereology Talks series, Prof. Esther Freeman is interviewed by a Congress delegate about the changing dynamics of the Mpox virus, formerly Monkey Pox. The 2022 outbreak, now with 90,000 global cases, challenges previous understandings with direct human-to-human spread. Prof. Freeman explores the controversial reclassification of Mpox as an STI, shares insights from her research, and emphasizes the need for continued vigilance among dermatologists. The episode concludes with a focus on vaccination and the urgency of early diagnosis for high-risk groups. Tune in to learn more!   Link to video version: https://www.youtube.com/playlist?list=PL2DbuyADMP5mFx4sZqS_vQtdTGOGIbwb1   You are invited to participate in our survey to improve the show. Your feedback is valued and appreciated to allow us to better serve our audience: https://eadv.org/eadv-podcast-survey/

Nail Unit Dermoscopy (Onychoscopy) in the Differential Diagnosis of Erythroderma. Zychowska M, Tognetti L. Journal of the European Academy of Dermatology and Venereology. 2023 May; 37(5):e663-5.Cross-Polarized Photography of the Nail Unit: A Practical Way to Eliminate Specular Reflections on the Nail Plate. Goktay F, Erdem O. Skin Appendage Disorders. 2023 Jun 1;9(4):313-6.How We Do It: Intraoperative Cross-Polarized Photography as an Alternative to Intraoperative Dermoscopy During Nail Surgery. Erdem O, Goktay F, Atis G, Erdemir VA. Dermatologic Surgery. 2022 May 12:10-97.

ARE SKINCARE ROUTINES THE KEY TO SOLVING YOUR SKIN WOES?

 Hello friends, and welcome back to Arthro-Pod! Today's episode is a look at a phenomenon many entomologists will encounter, even if they aren't ready to, known as delusory parasitosis. Also referred to as delusions of infestation and Ekbom's syndrome, this situation involves a person believing that their body and home are infested with some sort of biting or stinging pest, despite there being no evidence that is true. We're all predisposed to interpret certain signals as being caused by an insect or mite trying to crawl on us or bite us and unfortunately, sometimes this can further manifest as delusory parasitosis. Sufferers are often desperate for help and entomologists are often helpless to provide assistance. Today we wanted to outline some of the background of delusory parasitosis and talk about how entomologists can help, while also protecting themselves. Show NotesHinkle, N.C. 2000. Delusory parasitosis. American Entomologist 46(1): 17–25https://academic.oup.com/ae/article/46/1/17/2389588 Hinkle, N.C. 2010. Ekbom Syndrome: the challenge of “invisible bug” infestations. Annual Review of Entomology 55: 77–94. Doi: 10.1146/annurev.ento.54.110807.090514 Hinkle, N.C. 2011. Ekbom Syndrome: a delusional condition of “bugs in the skin”. Current Psychiatry Reports 13: 178–186.https://pubmed.ncbi.nlm.nih.gov/21344286/ Szepietowski, J.C., Salomon, J., Hrehorów, E., Pacan, P., Zalewska, A., and Sysa-Jȩdrzejowska, A. 2007. Delusional parasitosis in dermatological practice. Journal of the European Academy of Dermatology & Venereology 21(4): 462–465. https://pubmed.ncbi.nlm.nih.gov/17373971/ Questions? Comments? Follow the show on Twitter @Arthro_PodshowFollow the hosts on Twitter @bugmanjon, @JodyBugsmeUNL, and @MSkvarla36Get the show through Apple Podcast, Spotify, or your favorite podcatching app!If you can spare a moment, we appreciate when you subscribe to the show on those apps or when you take time to leave a review!Subscribe to our feed on Feedburner!  

In this episode of the Venereology Talks series, join Dr. Eija Hiltunen-Back, an esteemed authority on genital skin diseases and sexually transmitted infections (STIs), in conversation with Vladimir Grichishkin. Dr. Hiltunen-Back, a venereology specialist and adjunct professor at the University of Helsinki, delves into STI epidemiology and genital dermatology. Together, they discuss the resurgence of syphilis, uncovering its modern relevance and implications. Tune in to learn more about this crucial topic!   Link to video version: https://www.youtube.com/playlist?list=PL2DbuyADMP5mFx4sZqS_vQtdTGOGIbwb1   You are invited to participate in our survey to improve the show. Your feedback is valued and appreciated to allow us to better serve our audience: https://eadv.org/eadv-podcast-survey/  

In this episode, part of the special series Venereology Talks, Dr. Peter Greenhouse, a renowned expert in sexual health, discusses the current epidemiological situation on genital warts and HPV with medical student and HIV activist, Vladimir Grichishkin. They explore the varied recommendations regarding HPV vaccination, even in the same geographical region, and whether HPV vaccination should be offered regardless of age and gender. Dr. Greenhouse shares his insights and expertise on these important topics, drawing from his 48 years of experience in the field. Tune in to this informative podcast to learn more about these crucial issues in sexual health.   Link to video version: https://www.youtube.com/playlist?list=PL2DbuyADMP5mFx4sZqS_vQtdTGOGIbwb1   You are invited to participate in our survey to improve the show. Your feedback is valued and appreciated to allow us to better serve our audience: https://eadv.org/eadv-podcast-survey/

Este episodio tiene un invitado de lujo desde Madrid, España, el Dr. Antonio Torrelo.  Una eminencia en Dermatología Pediátrica como clínico, investigador, educador y mentor de muchas generaciones de Dermatólogos Pediatras en Europa y a nivel mundial.   El Dr. Antonio Torrelo es graduado en medicina desde 1988 y especialista en dermatología desde 1992. Realizó su especialidad en el Hospital Ramón y Cajal de Madrid. Desde 1992 es médico dermatólogo en el Servicio de Dermatología del Hospital Infantil del Niño Jesús de Madrid, y desde 2007 es Jefe de dicho servicio.  El Dr. Torrelo ja sido presidente del Grupo Español de Dermatología Pediátrica (2001-2004), de la European Society of Pediatric Dermatology (2017-2019) y de la International Society of Pediatric Dermatology (ISPD) (2013-2017). Fue presidente del Congreso Mundial de Dermatología Pediátrica en Madrid, 2013.  El Dr. Torrelo se desempeñó como Editor en Jefe de Actas Dermosifiliográficas (2002 a 2006) y Editor Asociado de Pediatric Dermatology (2007-2021). Pertenece al Comité Editorial del Journal of the American Academy of Dermatology (2010 a 2013 y 2018-presente). Actualmente es Editor en Jefe de la revista JEADV Clinical Practice.  El Dr. Torrelo ha actuado como editor asociado de Schachner LA, Hansen RC. Textbook of Pediatric Dermatology, 4ª edición; Editor principal de Schachner LA, Hansen RC. Textbook of Pediatric Dermatology, 5ª edición, 2023; Editor asociado de Bolognia J, Schaffer JV, Cerroni L. Dermatology, 4ª edición y 5ª edición (en preparación). También ha escrito o es coautor de más de 30 capítulos en libros de texto internacionales.  El Dr. Torrelo ha dictado conferencias en los congresos de la European Academy of Dermatology and Venereology (1993-2019), la European Society of Pediatric Dermatology (2002-2020), el Congreso Mundial de Dermatología Pediátrica (2001-2021) y en centenas de congresos y cursos internacionales adicionales, incluida la Society for Pediatric Dermatology (EE. UU.) en 2010 (The Esterly Lecture), 2011 (The Founders Lecture) y en 2021.  El Dr. Torrelo es autor o coautor de más de 330 artículos científicos en revistas indexadas en PubMed.  ¿Tienes algún comentario sobre este episodio o sugerencias de temas para un futuro podcast? Escríbenos a pediatrasenlinea@childrenscolorado.org.

People around the globe have protected their skin using a variety of substances throughout history. In the 19th and 20th centuries, deeper understanding of sunlight and the way it affects skin led to more protective sunscreen formulations.  Research: Aldahan AS, Shah VV, Mlacker S, Nouri K. “The History of Sunscreen.” JAMA Dermatol. 2015;151(12):1316. doi:10.1001/jamadermatol.2015.3011 Belmont, Trixie. “Suntans With Pay Off.” The Baltimore Sun. June 13, 1967. https://www.newspapers.com/image/377122417/?terms=%22franz%20greiter%22%20&match=1 Britannica, The Editors of Encyclopaedia. "Johann Wilhelm Ritter". Encyclopedia Britannica, 19 Jan. 2023, https://www.britannica.com/biography/Johann-Wilhelm-Ritter Diffey, B. “Has the sun protection factor had its day?.” BMJ (Clinical research ed.) 320,7228 (2000): 176-7. doi:10.1136/bmj.320.7228.176 Greiter, F. and Gschnait, F. “EFFECT OF UV LIGHT ON HUMANS.” Photochemistry and Photobiology. 1984. 39: 869-873. https://doi.org/10.1111/j.1751-1097.1984.tb08873.x Hodgskiss, Tammy. “What the use of ochre tells us about the capabilities of our African ancestry.” The Conversation. Sept. 7, 2015. https://theconversation.com/what-the-use-of-ochre-tells-us-about-the-capabilities-of-our-african-ancestry-47081 “History of Hamilton.” https://www.hamiltonsunandskin.com.au/history-of-hamilton Leach, Doreen, and Julie Beckwith. “The founders of dermatology: Robert WilIan and Thomas Bateman.” Journal of the Royal College of Physicians of London. Vol. 33, No. 6. November/December 1999. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665792/pdf/jrcollphyslond146949-0084.pdf MacEACHERN W.N. and O.F. JILLSON. “A Practical Sunscreen— ‘Red Vet Pet.'” Arch Dermatol. 1964;89(1):147–150. doi:10.1001/archderm.1964.01590250153027 Rathish, Shruthi, and Sebastian Criton. “Robert Willan – A True Pioneer.”  Department of Dermatology, Venereology and Leprosy, Amala Institute of Medical Sciences, Thrissur, Kerala,  April 22, 2019. https://jsstd.org/robert-willan-a-true-pioneer/ Rubin, Penny. “Only on Sun Days.” The Province. January 4, 1975. https://www.newspapers.com/image/501299818/?terms=%22franz%20greiter%22&match=1 “The science of sunscreen.” Harvard Health Publishing.  Feb 15, 2021. https://www.health.harvard.edu/staying-healthy/the-science-of-sunscreen Skin Cancer Foundation. “Ask the Expert: Does a High SPF Protect My Skin Better?”May 1. 2023. https://www.skincancer.org/blog/ask-the-expert-does-a-high-spf-protect-my-skin-better/ “Sunscreen: How to Help Protect Your Skin from the Sun.” FDA. https://www.fda.gov/drugs/understanding-over-counter-medicines/sunscreen-how-help-protect-your-skin-sun#spf “SUNSCREEN IN THE ENVIRONMENT:The History of Sunscreen's Effect on Corals.” Smithsonian Institute Oceans. https://ocean.si.edu/ecosystems/coral-reefs/sunscreen-environment “Sun Tan Free, by the Inch.” The San Francisco Examiner. June 18, 1967. https://www.newspapers.com/image/458648765/?terms=%22franz%20greiter%22&match=1 Svarc, Federico. "A brief illustrated history on sunscreens and sun protection" Pure and Applied Chemistry, vol. 87, no. 9-10, 2015, pp. 929-936. https://doi.org/10.1515/pac-2015-0303 Urbach, Frederick. “The historical aspects of sunscreens.” Journal of Photochemistry and Photobiology B: Biology. Volume 64, Issues 2–3. 2001.Pages 99-104. https://doi.org/10.1016/S1011-1344(01)00202-0. Urbach, F. “Franz Greiter – The Man and His Work.” Photobiology. 1991. https://doi.org/10.1007/978-1-4615-3732-8_82 See omnystudio.com/listener for privacy information.

Dr. Anil Kumar Jha is a MD in Dermatology, who specializes in Dermatology and Venereology. He is the founding chairman of DI Skin Health and Referral Center (DISHARC).

Notes from the Field: First Reported US Cases of Tinea Caused by Trichophyton indotineae—New York City, December 2021–March 2023. Caplan AS, et al Morbidity and Mortality Weekly Report. 2023 May 5;72(19):536.Onycholysis and purpuric nail striae in a child. Yang L, Wang T, Liu Y. Pediatric Dermatology. 2023 Apr 18. Nail involvement in Langerhans cell histiocytosis and its association with multisystem presentation and lung involvement. Bonometti A, Passoni E, Finotto S, Berti E. Indian Journal of Dermatology, Venereology and Leprology. 2021 Oct 23;87(6):850-4.

"Distinct patient characteristics and pathogenesis of fingernail only vs. fingernail and toenail onychomycosis in a retrospective single-centre academic study." Miller, Rhiannon C., and Shari R. Lipner. Journal of the European Academy of Dermatology and Venereology (2022)."DNA damage and somatic mutations in mammalian cells after irradiation with a nail polish dryer." Zhivagui, Maria, et al., Nature Communications 14.1 (2023): 276.

On this episode of JCMS Author Interviews, we take you to Verona, Italy for a conversation with Dr Paolo Gisondi about a very important topic: The Metabolic Aspects of Psoriasis. The conversation is based around Dr Gisondi's article in the May/June 2022 edition of the Journal of Cutaneous Medicine and Surgery titled: "Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis."As Kirk says about this conversation, "It's fascinating to learn how Dr Gisondi changed his practice over time. He's got an expertise and interest in the metabolic area surrounding psoriasis, and really has informed the rest of us internationally. He's made a difference."Dr Paolo Gisondi is an Associate Professor of Dermatology and Venereology and President of the Dermatology and Venereology Residence Program at the University Hospital of Verona, Italy.

"Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis." Gallo, Giuseppe, et al. Dermatologic Therapy (2022): e15917."Strategies for the Enhancement of Nail Plate Permeation of Drugs to Treat Onychomycosis." Gupta, Aditya K., et al. Journal of the European Academy of Dermatology and Venereology (2022).

What are the potential ways in which dermatologists can diminish the detrimental personal and community health impacts of climate change? In today's episode, Prof. Jan Gutermuth moderates the discussion with Prof. Eva Parker, a co-author of a recent commentary — published simultaneously in the International Journal of Dermatology, British Journal of Dermatology, Pediatric Dermatology and the Journal of the European Academy of Dermatology and Venereology — aiming to draw broader recognition of the climate crisis to members of the dermatology and venereology community. https://onlinelibrary.wiley.com/doi/10.1111/jdv.18416

What is the role of the medical professional community in addressing health-related (mis)information online? How can we help the audience differentiate facts from fiction? Join us as Dr. Sergio Vañó Galván dives into the ins and outs of growing a professional Dermatologist profile, including the pros and cons of being active on social media and best practice when sharing scientific information with a lay audience.

This podcast is only for use by healthcare professionals. This educational podcast has been fully sponsored by UCB and the content does not necessarily reflect the views of UCB. Speaker Disclosure: Prof. Paulo Gisondi has participated to boards and acted as a speaker for AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Eli-Lilly, Janssen, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, UCB Pharma. Privacy Policy: For further information on how UCB processes personal data, visit: https://www.ucb.com/Privacy-policy-for-Healthcare-Professionals This EMG-Health podcast explores options for treating females with psoriasis and questions the surrounding factors that must be taken into consideration. Featuring the expert opinion of Paolo Gisondi, Associate Professor of Dermatology and Venereology, University Hospital of Verona, Italy, this podcast explores sex-specific challenges in patients with psoriasis with articular manifestations.

Dr. Oana Spânu este Medic Primar Dermatolog, doctorand la UMF Carol Davila, a absolvit Universitatea de Medicină şi Farmacie Carol Davila, Bucureşti în anul 2001 şi a urmat rezidenţiatul în Dermatologie- Venerologie la Spitalul Universitar de Urgenţă Elias. Este și membru al World Society Interdisciplinary Anti-Aging Medicine, European Academy of Dermatology and Venereology, International Dermoscopy Society, Societatea Romana Dermatologie, Asociatia de Medicina Anti-Aging. Competente si experienta: Dermatologie-Venerologie, Dermatoscopie, Chirurgie Dermatologica, Dermatologie Estetica, Dermatocosmetologie, Laser in Dermatologie, Coordonator, Investigator Principal studii clinice multicentrice in Dermatocosmetologie si Dermatologie. Vorbim astăzi despre toate tipurile ten: atopice, uscate, deshidratate, accneic, gras, mixt si cum să avem o rutină corectă de îngrijire, cu produse adecvate și corect aplicate.

Dr. Oana Spânu este medic specialist Dermatologie, doctorand la UMF Carol Davila, a absolvit Universitatea de Medicină şi Farmacie Carol Davila, Bucureşti în anul 2001 şi a urmat rezidenţiatul în Dermatologie- Venerologie la Spitalul Universitar de Urgenţă Elias. Este și membru al World Society Interdisciplinary Anti-Aging Medicine, European Academy of Dermatology and Venereology, International Dermoscopy Society, Societatea Romana Dermatologie, Asociatia de Medicina Anti-Aging. Competente si experienta: Dermatologie-Venerologie, Dermatoscopie, Chirurgie Dermatologica, Dermatologie Estetica, Dermatocosmetologie, Laser in Dermatologie, Coordonator, Investigator Principal studii clinice multicentrice in Dermatocosmetologie si Dermatologie.

Dr. Macrene Alexiades holds three Harvard degrees, a BA in Biology, an MD and a PhD in Genetics; 25+ year research background; and runs her own esteemed Park Avenue private practice in dermatology and laser surgery, a research clinic, and a lab focusing on anti-aging skin care, acne, skin cancer, and lasers. She is an artist and sculptor and uses injectables to achieve a natural look in her patients. M.D., Ph.D. received her three degrees from Harvard University: a B.A. from Harvard University, where she was elected to Phi Beta Kappa and awarded the Fay Prize, the highest undergraduate honor; a M.D. from Harvard Medical School, and a Ph.D. in Geneticsfrom Harvard University. She is Associate Clinical Professor at Yale University and Adjunct Professor at Sigros Hospital, University of Athens. She was a Fulbright Scholar with a research award year in Europe. At Harvard, she excelled in portrait art and sculpture, but ultimately chose medicine and science, and was profiled in The New York Times and Vogue for her artistic skills in dermatology, injections and lasers. In medical school, she was honored with the Harvard Medical School Dean's Report and the Paul Dudley White Award. In graduate school, she received grants from the National Institutes of Health, National Eye Institute and Radcliffe College. As Chief Dermatology Resident at New York University School of Medicine, she was awarded the Husik Prize. She is a Fellow of the American Academy of Dermatology and American Society for Laser Medicine (ASLMS) and Surgery and a Goldman Circle Member. She has achieved the rare status of Double Board-Certification in Dermatology in the European Union as well as the U.S. She is a Castle Connolly Top Doctor, New York Magazine Top Doctor and featured in numerous Who's Who awards. She serves on numerous medical boards, conducts FDA clinical trials for Allergan and research for Lancome among many other pharmaceutical and cosmetic companies. She recently was awarded the Richard E. Fitzpatrick Award, the top laser prize for her research at ASLMS. She is Assistant Editor for the journal Dermatologic Surgery and Senior Associate Editor for the Journal of Drugs in Dermatology, and Editor & Reviewer for over 15 journals, including The New England Journal of Medicine, JAAD, JAMA Dermatology, Journal of Lasers in Medicine and Surgery, Journal of Cosmetic Surgery, British Journal of Dermatology and the Journal of the European Academy of Dermatology and Venereology. She has served as Chair of Research for the American Society for Dermatologic Surgery, Guest Editor-in-Chief of the Annual Laser Issue for the Journal of Drugs in Dermatology, and has been extensively biographed in Who's Who and recipient of the Lifetime Achievement Award and Industry Leaders Award.. --- Send in a voice message: https://anchor.fm/skincareanarchy/message Support this podcast: https://anchor.fm/skincareanarchy/support

In the run-up to the 30th Congress of the European Academy of Dermatology and Venereology, Prof Alexander Stratigos, talks about the accomplishments of the Academy in his first year as President and the challenges and opportunities brought about by the COVID-19 pandemic that have paved the way to a digital transformation and a strengthened voice in Europe.

Brian Diffey, BSc, AKC, PhD, DSc is Emeritus Professor of Photobiology in Dermatological Sciences, Institute of Cellular Medicine at the University of Newcastle, UK.During his career in the NHS, he established an internationally-respected research program in skin photobiology, particularly in the measurement of personal sun exposure; its effects in normal and diseased human skin; and ways to minimize excessive exposure, especially through the use of topical sunscreens.He has advised a number of bodies on sun exposure and skin health including the World Health Organization, Department of Health, and the Cancer Research UK SunSmart program, as well as patient support groups concerned with sun-related diseases such as melanoma, vitiligo and xeroderma pigmentosum.He invented both the UVA Star Rating for sunscreens in conjunction with Boots in the UK, and the Critical Wavelength adopted by the Food & Drug Administration in the USA as the sole measure of broad spectrum protection.In 1999 he was awarded the Medal of the Society of Cosmetic Scientists for his contributions to suncare, and in 2011 was honoured at the International Sun Protection Conference for significant innovation in the field of photoprotection.He is an honorary member of the British Association of Dermatologists, the Swedish Society for Dermatology and Venereology, and the European Society for Photodermatology. Research:Human safety review of "nano" titanium dioxide and zinc oxideCurrent Highlights About the Safety of Inorganic Nanomaterials in HealthcareReview of environmental effects of oxybenzone and other sunscreen active ingredientsFDA Trials Find Sunscreen Ingredients in Blood, but Risk Is UncertainUpdate About the Effects of the Sunscreen Ingredients Oxybenzone and Octinoxate on Humans and the EnvironmentHawaii and Other Jurisdictions Ban Oxybenzone or Octinoxate Sunscreens Based on the Confirmed Adverse Environmental Effects of Sunscreen Ingredients on Aquatic EnvironmentsNon-sunscreen photoprotection: antioxidants add value to a sunscreenOptimal sunscreen use, during a sun holiday with a very high ultraviolet index, allows vitamin D synthesis without sunburnThe effect of sunscreen on vitamin D: a reviewSunscreen recall: What the finding of a cancer-causing chemical means for youCurrent principles of sunscreen use in children Environmental Working Group's guide to sunscreen Darya's favorite all around sunscreen for outdoor activities: iS Clinical Eclipse SPF 50+  (this stuff is magic)Darya's favorite daily face sunscreen: Josh Rosebrook's Nutrient Day CreamDarya's favorite backup sunscreen for face and body: Rhonda Allison Daytime Defense SPF 30

FDA 批准靶向IL-23的单克隆抗体治疗银屑病Arthritis & Rheumatol 替格瑞洛治疗后骨关节炎风险的降低JAMA 生物力学鞋对膝骨关节炎患者膝关节疼痛的影响LANCET 非布司他与别嘌醇在痛风患者中的长期心血管安全性Nature子刊 抑制MEK使CD8+ T淋巴细胞重新编码为具有潜在抗肿瘤特性的记忆干细胞替达珠单抗（tildrakizumab）替达珠单抗（tildrakizumab）是人源化IgG1x单克隆抗体，靶向IL-23的p19亚基并阻断其与IL-23受体结合，抑制细胞因子与趋化因子释放。2018年3月FDA批准替达珠单抗用于治疗成人中重度斑块型银屑病。《reSURFACE1和reSURFACE2研究52周的综合分析：替达珠单抗治疗中重度银屑病52周的疗效的3期临床研究》Journal of European Academy of Dermatology & Venereology，2019年12月 (1) reSURFACE1和reSURFACE2研究的目的是观察替达珠单抗治疗中重度银屑病的疗效，前28周的结果已经证实了替达珠单抗的疗效，这篇文章报告了随访52周的结果，旨在评价治疗对患者皮肤科生活质量评分（DLQI）和银屑病面积和严重程度指数（PASI）评分的影响。两项研究中使用替达珠单抗100 mg或200 mg治疗的1156位患者，在第28周合并，然后根据第28周时的PASI评分改善程度分为5组：0-49分、50-74分、75-89分、90-99分和100分。第28周，替达珠单抗100 mg组和200 mg组根据PASI评分改善程度分组后的患者比例分别为8.3%、14.3%、23.8%、30.4%、23.1%，和4.0%、18.1%、19.6%、29.1%、29.3%。第28周疗效较差的、PASI改善50的患者中，持续使用相同剂量的替达珠单抗至第52周，PASI评分持续改善。两种剂量都观察到了类似的结果。28周时PASI改善较好的患者中，DLQI 0/1的比例较高，且维持或改善至52周。然而，并不是所有PASI改善100患者的DLQI都为0/1。结论：替达珠单抗疗效较差的患者可在第8周确定，疗效好、PASI评分改善≥90的患者通常可在第4周确定。第28周PASI改善水平与生活质量改善相关。骨关节炎骨关节炎（osteoarthritis，OA）是最常见的关节炎。发病机制中有很多重要的因素，包括生物力学因素、促炎因子和蛋白酶等。症状主要是特征性关节组织病理改变所引起的疼痛和关节功能改变，所有的OA患者都存在关节软骨、骨骼、滑膜和软组织的病理表现。《回顾性分析：与氯吡格雷相比，替格瑞洛治疗后骨关节炎风险的降低》Arthritis & Rheumatol，2020年11月 (2)细胞外腺苷具有抗炎作用，在动物模型中可预防和治疗骨关节炎。替格瑞洛和氯吡格雷都用于冠心病患者，但只有替格瑞洛增加了细胞外腺苷水平。这项研究是为了确定治疗替格瑞洛是否与降低骨关节炎风险有关。研究纳入替格瑞洛或氯吡格雷治疗≥90天的、没有关节炎病史的、21000例患者。平均治疗天数分别为287天和284天。两组患者的平均年龄均为64岁，73%为男性。多变量Cox回归分析估计，与氯吡格雷相比，替格瑞洛治疗后发生OA的危险比为0.71(95%可信区间0.64-0.79)(P < 0.001)。结论：在5年的随访中，与氯吡格雷治疗相比，替格瑞洛治疗降低了骨关节炎发病风险达29%，这可能与我们假设接受替格瑞洛的患者中OA的减少可能部分是由于细胞外腺苷水平的增加。《软骨缺失会导致骨关节炎疼痛吗？如果会，疼痛程度是多少?》Annals of Rheumatic Disease，2020年9月 (3)虽然骨关节炎的治疗重点是软骨保护，但目前尚不清楚预防软骨损失能在多大程度上减轻关节疼痛。研究量化了骨髓病变和滑膜炎后软骨损失、和膝关节疼痛恶化之间的关系，并检查了这些因素在多大程度上介导了这种关联。研究人员在基线、12个月和24个月时，对600例膝关节MRI定量、半定量测量骨关节炎的结构特征。定量的计算了内侧软骨厚度的变化、软骨损失情况、使用西安大略和麦克马斯特大学骨关节炎指数疼痛评分（WOMAC疼痛评分）评价疼痛程度。随访24个月，软骨厚度的减少与疼痛的轻微恶化显著相关。例如，两年内软骨厚度减少0.1mm，WOMAC疼痛增加0.32。软骨厚度的减少与疼痛的关系是通过滑膜炎的改变，而不是骨髓病变的改变。亚分析结果相似。结论：软骨厚度的减少只与少量的膝关节疼痛恶化有关，这种关联部分是由滑膜炎恶化引起的。通过软骨保护减少膝盖疼痛可能是难以实现的。骨关节炎的治疗膝关节骨性关节炎的治疗方法包括非药物治疗、药物治疗和手术，旨在缓解疼痛、改善关节功能以及改变骨关节炎进展的危险因素。尽管研究很多，但改变疾病病程的疗法效果欠佳。轻度骨性关节炎着重体重管理、镇痛、局部物理治疗；中重度骨性关节炎着重情绪疏导、镇痛、关节内注射类固醇、运动（建议水中锻炼，耐受性比地面锻炼好）和手术。《VITAL研究：补充维生素D和ω-3脂肪酸对老年慢性膝盖疼痛的影响》Arthritis & Rheumatol，2020年11月 (4)膝痛是成人骨关节炎的常见病因。该研究的目的是评价维生素D、ω-3脂肪酸治疗膝关节疼痛的效果。这项双盲、安慰剂对照的研究纳入25,871名参与者，按照2x2设计随机接受维生素D或ω-3脂肪酸，随机化之前，确定了一个膝盖疼痛的亚组，这组人群共1398人，平均年龄67岁，66%为女性，根据WOMAC评分评价关节疼痛程度。基线时，WOMAC疼痛评分平均值为37，平均随访时间为5.3年后，WOMAC疼痛评分在维生素D组、ω-3脂肪酸组和安慰剂组之间没有差异。随着时间的推移，补充维生素D和ω-3脂肪酸对WOMAC功能或僵硬评分也没有显著影响。结论：在慢性膝关节疼痛的大样本中，补充维生素D和ω-3脂肪酸持续5.3年并不能减轻膝关节疼痛、或改善关节功能或僵硬。《随机、双盲、安慰剂对照试验：白细胞介素-1β抑制对髋关节和膝关节置换术发生率的影响》Annals of Internal Medicine，2020年10月 (5) 研究的目的是确定IL-1抑制卡那单抗是否减少全髋关节或膝关节置换术的发生率。研究纳入1061例CANTOS研究的参与者，随机给予安慰剂、或卡那单抗50mg、150mg或300mg ip 三个月一次。平均随访3.7年，与安慰剂相比，卡那单抗组的关节置换的风险比分别为：50mg组为0.60，150mg组为0.53，300 mg组为0.60，均有统计学意义。将治疗组数据合并，关节置换发生率为0.31/100人年，安慰剂组为0.54例/100人年（风险比 0.58，P=0.001）。结论：该随机对照试验的探索性分析结果支持进一步研究IL-1抑制治疗大型关节骨性关节炎。《随机对照研究：膝关节骨性关节炎的物理治疗与糖皮质激素注射比较》New England Journal of Medicine，2020年4月 (6)物理治疗和关节内注射糖皮质激素已被证明对膝骨关节炎有临床疗效。该研究的目的是评价这两种疗法在缓解疼痛、改善身体功能方面的短期和长期效果。这项随机试验纳入单膝或双膝骨关节炎患者共156人，平均年龄56岁，随机接受糖皮质激素注射或接受物理治疗。基线WOMAC功能或僵硬度评分平均值，糖皮质激素注射组为108.8分，物理治疗组为107.1分；1年时的平均值分别为55.8分和37.0分。组间平均差异为18.8分，物理治疗更好。结论：与接受关节内糖皮质激素注射的膝关节骨性关节炎患者相比，接受物理治疗的膝关节骨性关节炎患者在1年的疼痛和功能残疾更少。《BIOTOK研究：生物力学鞋对膝骨关节炎患者膝关节疼痛的影响》JAMA，2020年5月 (7)研究的目的是评价个体化校准的生物力学鞋疗法是否可能改善有症状性的、膝骨关节炎患者的疼痛和功能。这项随机临床试验纳入症状性膝关节骨关节炎患者220名，平均年龄65.2岁，给予生物力学鞋治疗或安慰剂治疗，随访24周。随访24周时，生物力学鞋组的标准化WOMAC疼痛评分平均值从4.3提高到1.3，对照组鞋组从4.0提高到2.6（P 50岁的、膝关节骨关节炎和软骨下骨髓病变的223名成年患者，平均年龄62岁，女性52%。随机分组，分别在试验开始时和12个月的时候静脉滴注一次5mg唑来膦酸组或100ml生理盐水作为安慰剂。随访24个月，唑来膦酸组和安慰剂组的胫股软骨体积变化无显著差异（P = 0.50）。次要结果的组间差异均无统计学意义，包括膝关节疼痛评分、WOMAC骨关节炎指数、骨髓病灶大小变化。唑来膦酸的不良事件比安慰剂更常见。结论：症状性膝骨关节炎和骨髓病变患者中，每年注射唑来膦酸并没有显著减少软骨体积损失。这些发现不支持使用唑来膦酸治疗膝骨关节炎。《随机对照研究：姜黄提取物治疗膝关节骨关节炎症状及渗出性滑膜炎的疗效观察》Annals of Internal Medicine，2020年12月 (9)研究的目的是探讨姜黄提取物对症状性、膝关节骨性关节炎和膝关节渗出性滑膜炎的疗效。这项单中心研究招募了70名参与者，连续12周，每天2粒姜黄提取物或安慰剂。12周后，与安慰剂相比，姜黄提取物改善视觉模拟疼痛（VAS）评分的幅度为-9.1mm（P = 0.039），但没有改变渗出性滑膜炎体积（3.2mL）。姜黄提取物还可改善WOMAC膝关节疼痛评分（P = 0.006），但没有改善MRI腓骨外侧软骨T2松弛时间（−0.4 ms）。两组不良事件发生率相似（P = 0.16）结论：对于膝关节疼痛，姜黄提取物比安慰剂更有效，但不影响膝关节渗出性滑膜炎或软骨成分。需要更大样本量的多中心试验来评估这些发现的临床意义。痛风痛风是尿酸单钠结晶沉积病，其生化特点是细胞外液尿酸盐浓度达到饱和，血液中表现为高尿酸血症，即血尿酸盐浓度超过400μmol/L，该水平接近于尿酸盐的溶解度极限。痛风的临床表现包括：炎症性关节炎的反复发作、慢性关节病、尿酸盐结晶累积形成痛风石沉积、尿酸性肾结石等。急性期止痛，可以使用全身或关节内糖皮质激素、NSAID、秋水仙碱，难治性痛风发作可尝试使用抑制IL-1β的生物制剂（欧盟已批准卡那单抗治疗难治性痛风发作）。缓解期降尿酸，可以使用别嘌醇、非布司他、丙磺舒、苯溴马龙或聚乙二醇重组尿酸酶。《FAST研究：非布司他与别嘌醇在痛风患者中的长期心血管安全性》LANCET，2020年11月 (10)这项前瞻性、随机、开放、非劣效研究，纳入≥60岁、已经接受别嘌醇治疗的、合并心血管危险因素的患者，共6128人。患者平均年龄71岁，85%为男性，33.4%有心血管疾病病史。被随机分配别嘌醇或非布司他治疗，中位随访时间为1467天。在非致死性心梗或急性冠脉综合征住院的发生率方面，非布司他为1·72次/100人年，低于别嘌醇2·05次/100人年（风险比 0·85，p

FDA 批准靶向IL-23的单克隆抗体治疗银屑病Arthritis & Rheumatol 替格瑞洛治疗后骨关节炎风险的降低JAMA 生物力学鞋对膝骨关节炎患者膝关节疼痛的影响LANCET 非布司他与别嘌醇在痛风患者中的长期心血管安全性Nature子刊 抑制MEK使CD8+ T淋巴细胞重新编码为具有潜在抗肿瘤特性的记忆干细胞替达珠单抗（tildrakizumab）替达珠单抗（tildrakizumab）是人源化IgG1x单克隆抗体，靶向IL-23的p19亚基并阻断其与IL-23受体结合，抑制细胞因子与趋化因子释放。2018年3月FDA批准替达珠单抗用于治疗成人中重度斑块型银屑病。《reSURFACE1和reSURFACE2研究52周的综合分析：替达珠单抗治疗中重度银屑病52周的疗效的3期临床研究》Journal of European Academy of Dermatology & Venereology，2019年12月 (1) reSURFACE1和reSURFACE2研究的目的是观察替达珠单抗治疗中重度银屑病的疗效，前28周的结果已经证实了替达珠单抗的疗效，这篇文章报告了随访52周的结果，旨在评价治疗对患者皮肤科生活质量评分（DLQI）和银屑病面积和严重程度指数（PASI）评分的影响。两项研究中使用替达珠单抗100 mg或200 mg治疗的1156位患者，在第28周合并，然后根据第28周时的PASI评分改善程度分为5组：0-49分、50-74分、75-89分、90-99分和100分。第28周，替达珠单抗100 mg组和200 mg组根据PASI评分改善程度分组后的患者比例分别为8.3%、14.3%、23.8%、30.4%、23.1%，和4.0%、18.1%、19.6%、29.1%、29.3%。第28周疗效较差的、PASI改善50的患者中，持续使用相同剂量的替达珠单抗至第52周，PASI评分持续改善。两种剂量都观察到了类似的结果。28周时PASI改善较好的患者中，DLQI 0/1的比例较高，且维持或改善至52周。然而，并不是所有PASI改善100患者的DLQI都为0/1。结论：替达珠单抗疗效较差的患者可在第8周确定，疗效好、PASI评分改善≥90的患者通常可在第4周确定。第28周PASI改善水平与生活质量改善相关。骨关节炎骨关节炎（osteoarthritis，OA）是最常见的关节炎。发病机制中有很多重要的因素，包括生物力学因素、促炎因子和蛋白酶等。症状主要是特征性关节组织病理改变所引起的疼痛和关节功能改变，所有的OA患者都存在关节软骨、骨骼、滑膜和软组织的病理表现。《回顾性分析：与氯吡格雷相比，替格瑞洛治疗后骨关节炎风险的降低》Arthritis & Rheumatol，2020年11月 (2)细胞外腺苷具有抗炎作用，在动物模型中可预防和治疗骨关节炎。替格瑞洛和氯吡格雷都用于冠心病患者，但只有替格瑞洛增加了细胞外腺苷水平。这项研究是为了确定治疗替格瑞洛是否与降低骨关节炎风险有关。研究纳入替格瑞洛或氯吡格雷治疗≥90天的、没有关节炎病史的、21000例患者。平均治疗天数分别为287天和284天。两组患者的平均年龄均为64岁，73%为男性。多变量Cox回归分析估计，与氯吡格雷相比，替格瑞洛治疗后发生OA的危险比为0.71(95%可信区间0.64-0.79)(P < 0.001)。结论：在5年的随访中，与氯吡格雷治疗相比，替格瑞洛治疗降低了骨关节炎发病风险达29%，这可能与我们假设接受替格瑞洛的患者中OA的减少可能部分是由于细胞外腺苷水平的增加。《软骨缺失会导致骨关节炎疼痛吗？如果会，疼痛程度是多少?》Annals of Rheumatic Disease，2020年9月 (3)虽然骨关节炎的治疗重点是软骨保护，但目前尚不清楚预防软骨损失能在多大程度上减轻关节疼痛。研究量化了骨髓病变和滑膜炎后软骨损失、和膝关节疼痛恶化之间的关系，并检查了这些因素在多大程度上介导了这种关联。研究人员在基线、12个月和24个月时，对600例膝关节MRI定量、半定量测量骨关节炎的结构特征。定量的计算了内侧软骨厚度的变化、软骨损失情况、使用西安大略和麦克马斯特大学骨关节炎指数疼痛评分（WOMAC疼痛评分）评价疼痛程度。随访24个月，软骨厚度的减少与疼痛的轻微恶化显著相关。例如，两年内软骨厚度减少0.1mm，WOMAC疼痛增加0.32。软骨厚度的减少与疼痛的关系是通过滑膜炎的改变，而不是骨髓病变的改变。亚分析结果相似。结论：软骨厚度的减少只与少量的膝关节疼痛恶化有关，这种关联部分是由滑膜炎恶化引起的。通过软骨保护减少膝盖疼痛可能是难以实现的。骨关节炎的治疗膝关节骨性关节炎的治疗方法包括非药物治疗、药物治疗和手术，旨在缓解疼痛、改善关节功能以及改变骨关节炎进展的危险因素。尽管研究很多，但改变疾病病程的疗法效果欠佳。轻度骨性关节炎着重体重管理、镇痛、局部物理治疗；中重度骨性关节炎着重情绪疏导、镇痛、关节内注射类固醇、运动（建议水中锻炼，耐受性比地面锻炼好）和手术。《VITAL研究：补充维生素D和ω-3脂肪酸对老年慢性膝盖疼痛的影响》Arthritis & Rheumatol，2020年11月 (4)膝痛是成人骨关节炎的常见病因。该研究的目的是评价维生素D、ω-3脂肪酸治疗膝关节疼痛的效果。这项双盲、安慰剂对照的研究纳入25,871名参与者，按照2x2设计随机接受维生素D或ω-3脂肪酸，随机化之前，确定了一个膝盖疼痛的亚组，这组人群共1398人，平均年龄67岁，66%为女性，根据WOMAC评分评价关节疼痛程度。基线时，WOMAC疼痛评分平均值为37，平均随访时间为5.3年后，WOMAC疼痛评分在维生素D组、ω-3脂肪酸组和安慰剂组之间没有差异。随着时间的推移，补充维生素D和ω-3脂肪酸对WOMAC功能或僵硬评分也没有显著影响。结论：在慢性膝关节疼痛的大样本中，补充维生素D和ω-3脂肪酸持续5.3年并不能减轻膝关节疼痛、或改善关节功能或僵硬。《随机、双盲、安慰剂对照试验：白细胞介素-1β抑制对髋关节和膝关节置换术发生率的影响》Annals of Internal Medicine，2020年10月 (5) 研究的目的是确定IL-1抑制卡那单抗是否减少全髋关节或膝关节置换术的发生率。研究纳入1061例CANTOS研究的参与者，随机给予安慰剂、或卡那单抗50mg、150mg或300mg ip 三个月一次。平均随访3.7年，与安慰剂相比，卡那单抗组的关节置换的风险比分别为：50mg组为0.60，150mg组为0.53，300 mg组为0.60，均有统计学意义。将治疗组数据合并，关节置换发生率为0.31/100人年，安慰剂组为0.54例/100人年（风险比 0.58，P=0.001）。结论：该随机对照试验的探索性分析结果支持进一步研究IL-1抑制治疗大型关节骨性关节炎。《随机对照研究：膝关节骨性关节炎的物理治疗与糖皮质激素注射比较》New England Journal of Medicine，2020年4月 (6)物理治疗和关节内注射糖皮质激素已被证明对膝骨关节炎有临床疗效。该研究的目的是评价这两种疗法在缓解疼痛、改善身体功能方面的短期和长期效果。这项随机试验纳入单膝或双膝骨关节炎患者共156人，平均年龄56岁，随机接受糖皮质激素注射或接受物理治疗。基线WOMAC功能或僵硬度评分平均值，糖皮质激素注射组为108.8分，物理治疗组为107.1分；1年时的平均值分别为55.8分和37.0分。组间平均差异为18.8分，物理治疗更好。结论：与接受关节内糖皮质激素注射的膝关节骨性关节炎患者相比，接受物理治疗的膝关节骨性关节炎患者在1年的疼痛和功能残疾更少。《BIOTOK研究：生物力学鞋对膝骨关节炎患者膝关节疼痛的影响》JAMA，2020年5月 (7)研究的目的是评价个体化校准的生物力学鞋疗法是否可能改善有症状性的、膝骨关节炎患者的疼痛和功能。这项随机临床试验纳入症状性膝关节骨关节炎患者220名，平均年龄65.2岁，给予生物力学鞋治疗或安慰剂治疗，随访24周。随访24周时，生物力学鞋组的标准化WOMAC疼痛评分平均值从4.3提高到1.3，对照组鞋组从4.0提高到2.6（P 50岁的、膝关节骨关节炎和软骨下骨髓病变的223名成年患者，平均年龄62岁，女性52%。随机分组，分别在试验开始时和12个月的时候静脉滴注一次5mg唑来膦酸组或100ml生理盐水作为安慰剂。随访24个月，唑来膦酸组和安慰剂组的胫股软骨体积变化无显著差异（P = 0.50）。次要结果的组间差异均无统计学意义，包括膝关节疼痛评分、WOMAC骨关节炎指数、骨髓病灶大小变化。唑来膦酸的不良事件比安慰剂更常见。结论：症状性膝骨关节炎和骨髓病变患者中，每年注射唑来膦酸并没有显著减少软骨体积损失。这些发现不支持使用唑来膦酸治疗膝骨关节炎。《随机对照研究：姜黄提取物治疗膝关节骨关节炎症状及渗出性滑膜炎的疗效观察》Annals of Internal Medicine，2020年12月 (9)研究的目的是探讨姜黄提取物对症状性、膝关节骨性关节炎和膝关节渗出性滑膜炎的疗效。这项单中心研究招募了70名参与者，连续12周，每天2粒姜黄提取物或安慰剂。12周后，与安慰剂相比，姜黄提取物改善视觉模拟疼痛（VAS）评分的幅度为-9.1mm（P = 0.039），但没有改变渗出性滑膜炎体积（3.2mL）。姜黄提取物还可改善WOMAC膝关节疼痛评分（P = 0.006），但没有改善MRI腓骨外侧软骨T2松弛时间（−0.4 ms）。两组不良事件发生率相似（P = 0.16）结论：对于膝关节疼痛，姜黄提取物比安慰剂更有效，但不影响膝关节渗出性滑膜炎或软骨成分。需要更大样本量的多中心试验来评估这些发现的临床意义。痛风痛风是尿酸单钠结晶沉积病，其生化特点是细胞外液尿酸盐浓度达到饱和，血液中表现为高尿酸血症，即血尿酸盐浓度超过400μmol/L，该水平接近于尿酸盐的溶解度极限。痛风的临床表现包括：炎症性关节炎的反复发作、慢性关节病、尿酸盐结晶累积形成痛风石沉积、尿酸性肾结石等。急性期止痛，可以使用全身或关节内糖皮质激素、NSAID、秋水仙碱，难治性痛风发作可尝试使用抑制IL-1β的生物制剂（欧盟已批准卡那单抗治疗难治性痛风发作）。缓解期降尿酸，可以使用别嘌醇、非布司他、丙磺舒、苯溴马龙或聚乙二醇重组尿酸酶。《FAST研究：非布司他与别嘌醇在痛风患者中的长期心血管安全性》LANCET，2020年11月 (10)这项前瞻性、随机、开放、非劣效研究，纳入≥60岁、已经接受别嘌醇治疗的、合并心血管危险因素的患者，共6128人。患者平均年龄71岁，85%为男性，33.4%有心血管疾病病史。被随机分配别嘌醇或非布司他治疗，中位随访时间为1467天。在非致死性心梗或急性冠脉综合征住院的发生率方面，非布司他为1·72次/100人年，低于别嘌醇2·05次/100人年（风险比 0·85，p

Being the Editor-in-Chief of the Journal of the European Academy of Dermatology and Venereology is a fulfilling venture, but looking to the future to engage and inspire doctors and researchers takes a forward-thinking approach. Join us as we speak with Prof. Johannes Ring about his experience, approach and new projects.

The EADV is launching a podcast. Join us for interviews with established, and up and coming doctors and researchers in the fields of Dermatology and Venereology.

A Obiettivo Salute risveglio torniamo a parlare di Covid. E lo facciamo analizzando due ricerche. Uno studio pubblicato sul “The Journal of The European Academy of Dermatology and Venereology” ha dimostrato che anche la pelle può essere un bersaglio dell’infezione e le manifestazioni cutanee possono aiutare quindi a individuare i soggetti asintomatici. Ne parliamo con il dottor Fabrizio Fantini, direttore dell’Unità Ospedaliera Complessa di Dermatologia dell’Ospedale di Lecco, che ha coordinato la ricerca. Per saperne di più: ADOI (Associazione Dermatologi Ospedalieri Italiani) E poi con il dottor Lorenzo Azzi, ricercatore in malattie odontostomatologiche all'Università dell'Insubria di Varese, parliamo del Test rapido salivare (Trs) in grado di rilevare, nell’arco di pochissimi minuti, la presenza del Coronavirus: un nuovo strumento diagnostico che, nella fase 2 dell’emergenza, può essere strategico per la riapertura in sicurezza delle attività sociali e produttive

In 1495, a mysterious and deadly plague struck the city of Naples. Over the next 500 years, the medical attempts to understand and treat this new disease -- syphilis -- would mold and shape medicine in surprising ways. In this episode, Tony Breu and I will perform an historical and physiological biography of syphilis, covering the development of germ theory, epic poetry, mercury saunas, intentionally infecting patients with malaria, magic bullets, and lots and lots of experiments on poor rabbits. This presentation was performed live at the American College of Physicians’ national meeting in Philadelphia on April 11, 2019.   Sources (WARNING -- LONG LIST):   Swain, K. ‘Extraordinarily arduous and fraught with danger’: syphilis, Salvarsan, and general paresis of the insane. Lancet Psychiatry 5, (2018).   Kępa, M. et al. Analysis of mercury levels in historical bone material from syphilitic subjects – pilot studies (short report). Kępa Małgorzata 69, 367-377(11) (2012).   Forrai, J. Syphilis - Recognition, Description and Diagnosis. (2011). doi:10.5772/24205   Parascandola, J. From mercury to miracle drugs: syphilis therapy over the centuries. Pharm Hist 51, 14–23 (2009).   Eisler, C. Who Is Dürer’s ‘Syphilitic Man’? Perspect Biol Med 52, 48–60 (2009).   Rothschild, B. M. History of Syphilis. Clin Infect Dis 40, 1454–1463 (2005).   Schwartz, R. S. Paul Ehrlich’s Magic Bullets. New Engl J Medicine 350, 1079–1080 (2004).   Fee, E. The wages of sin. Lancet 354, SIV61 (1999).   O’Shea, J. ‘Two Minutes with Venus, Two Years with Mercury’-Mercury as an Antisyphilitic Chemotherapeutic Agent. J Roy Soc Med 83, 392–395 (1989).   Mahoney, J., Arnold, R., Sterner, B. L., Harris, A. & Zwally, M. Penicillin Treatment of Early Syphilis: II. Jama 251, 2005–2010 (1984).   Waugh, M. Role played by Italy in the history of syphilis. Sex Transm Infect 58, 92–95 (1982).   Thorburn, A. Fritz Richard Schaudinn, 1871-1906: protozoologist of syphilis. Sex Transm Infect 47, 459–461 (1971).   CROSBY, A. W. The Early History of Syphilis: A Reappraisal. Am Anthropol 71, 218–227 (1969).   Clark, E. G. & Danbolt, N. The Oslo study of the natural history of untreated syphilis An epidemiologic investigation based on a restudy of the Boeck-Bruusgaard material a review and appraisal. J Chron Dis 2, 311–344 (1955).   MUNGER, R. S. Guaiacum, the Holy Wood from the New World. J Hist Med All Sci IV, 196–229 (1949).   Thomas, E. & r, W. Rapid Treatment of Early Syphilis with Multiple Injections of Mapharsen. J Nerv Ment Dis 99, 88 (1944).   WIEDER, L., FOERSTER, O. & FOERSTER, H. MAPHARSEN IN THE TREATMENT OF SYPHILIS: FURTHER EXPERIENCES. Arch Dermatol Syph 35, 402–413 (1937).   THON, L. SHOULD THE INTERNIST KNOW SYPHILIS? J Amer Med Assoc 97, 994–996 (1931).   Sarton, G. The Earliest Printed Literature on Syphilis, being Ten Tractates from the Years 1495-1498. Karl Sudhoff , Charles Singer , Henry E. Sigerist. Isis 8, 351–354 (1926).   COLE, H., GERICKE, A. & SOLLMANN, T. THE TREATMENT OF SYPHILIS BY MERCURY INHALATIONS: HISTORY, METHOD AND RESULTS. Arch Dermatol Syph 5, 18–33 (1922).   Mason, U. Observation: Use and Abuse of Salvarsan. J Natl Med Assoc 3, 340–3 (1911).   Fleming, A. & Colebrook, L. ON THE USE OF SALVARSAN IN THE TREATMENT OF SYPHILIS. Lancet 177, 1631–1634 (1911).   Evans, A. The Treatment of Syphilis by Salvarsan (Dioxy-diamido-arseno-benzol). Brit Med J 1, 617 (1911).   Boeck, W. History, Theory and Practice of Syphilisation. New Engl J Medicine 73, 20–25 (1865).   Veale, H. Remarks on Syphilis and Its Treatment. Edinb Medical J 10, 10–26 (1864).   LaFond RE and Lukehart SA, Biological Basis for Syphilis. Clinical Microbiology Reviews 2006.   Secher L et al, Treponema pallidum in peripheral nerve tissue of syphilitic chancres. Acta dermato-venereologica 1982.  Hollander DH, Turner TB, The role of temperature in experimental treponemal infection. American journal of syphilis, gonorrhea, and venereal diseases, 1954   Eagle H, et al. The effect of hyperpyrexia on the therapeutic efficacy of penicillin in experimental syphilis. American journal of syphilis, gonorrhea, and venereal diseases, 1947.   Kampmeier RH, Syphilis therapy: an historical perspective. Journal of the American Venereal Disease Association 1976.   Pachner AR, Spirochetal Diseases of the CNS. Neurologic clinics, 1986.   Sell S et al, Experimental syphilitic orchitis in rabbits: ultrastructural appearance of Treponema pallidum during phagocytosis and dissolution by macrophages in vivo. Laboratory investigation; a journal of technical methods and pathology, 1982.   Taylor SH, Diuretics in cardiovascular therapy. Perusing the past, practising in the present, preparing for the future. Zeitschrift für Kardiologie, 1985.   Ovchinnikov NM, [Treponema pallidum in peripheral nerves of rabbit syphiloma]. Vestnik dermatologii i venerologii, 1975.   Cheek DB, Wu F, The Effect of Calomel on Plasma Epinephrine in the Rat and the Relationship to Mechanisms in Pink Disease, Archives of Disease in Childhood, 1959   Vogl A, The discovery of the organic mercurial diuretics, American Heart Journal, 1950   Schwemlein GX et al, Penicillin and fever therapy in early syphilis, Journal of the American Medical Association, 1948.   Stringham JS, On the Diuretic Effects of Mercury in a Case of Syphilis. The Medical and physical journal, 1807   Evanson RL et al, Effect of mercurial diuretics on tubular sodium and potassium transport in the dog. The American journal of physiology, 1972   Sell S and Salman J, Demonstration of Treponema pallidum in Axons of Cutaneous Nerves in Experimental Chancres of Rabbits, Sexually Transmitted Diseases, 1992   Penn CW, Avoidance of Host Defences by Treponema pallidum in Situ and on Extraction from Infected Rabbit Testes, Microbiology 1981.   Beutler B and Munford RS, Tumor Necrosis Factor and the Jarisch–Herxheimer Reaction, The New England Journal of Medicine 1996.   Radolf JD et al, Treponema pallidum: doing a remarkable job with what it's got. Trends in Microbiology, 1999   Tight RR, Perkins RL, Treponema pallidum infection in subcutaneous polyethylene chambers in rabbits. Infection and immunity, 1976   Salazar JC et al, Treponema pallidum Elicits Innate and Adaptive Cellular Immune Responses in Skin and Blood during Secondary Syphilis: A Flow-Cytometric Analysis. The Journal of Infectious Diseases, 2007   Azevedo BF et al, Toxic Effects of Mercury on the Cardiovascular and Central Nervous Systems. Journal of Biomedicine and Biotechnology 2012,   Clarkson TW and Magos L, The Toxicology of Mercury and Its Chemical Compounds, Critical Reviews in Toxicology 2008.   Fitzgerald TJ, The Th1/Th2-like switch in syphilitic infection: is it detrimental? Infection and immunity, 1992   Batterman RC et al, THE SUBCUTANEOUS ADMINISTRATION OF MERCAPTOMERIN (THIOMERIN®): Effective Mercurial Diuretic for the Treatment of Congestive Heart Failure. Journal of the American Medical Association, 1949   Batterman RC, The status of mercurial diuretics for the treatment of congestive heart failure. American Heart Journal, 1951   Bleich HL et al, The Role of Regional Body Temperature in the Pathogenesis of Disease, The New England Journal of Medicine, 1981   Vander Veer JB et al, The Prolonged Use of an Oral Mercurial Diuretic in Ambulatory Patients with Congestive Heart Failure. Circulation 1950   Cox DL et al, The outer membrane, not a coat of host proteins, limits antigenicity of virulent Treponema pallidum. Infection and immunity, 1992.   Fildes P, The Mechanism of the Anti-bacterial Action of Mercury. Br J Exp Pathol, 1940   Clarkson TW, THE MECHANISM OF ACTION OF MERCURIAL DIURETICS IN RATS; THE METABOLISM OF 203Hg‐LABELLED CHLORMERODRIN. British Journal of Pharmacology and Chemotherapy, 1965   Engelkens HJ et al, The localisation of treponemes and characterisation of the inflammatory infiltrate in skin biopsies from patients with primary or secondary syphilis, or early infectious yaws. Genitourinary Medicine, 1993   Belum GR et al, The Jarisch–Herxheimer reaction: Revisited. Travel Medicine and Infectious Disease, 2013   Arando M et al, The Jarisch–Herxheimer reaction in syphilis: could molecular typing help to understand it better? Journal of the European Academy of Dermatology and Venereology, 2018.   Butler T, The Jarisch–Herxheimer Reaction After Antibiotic Treatment of Spirochetal Infections: A Review of Recent Cases and Our Understanding of Pathogenesis. The American Journal of Tropical Medicine and Hygiene, 2016   Carlson JA et al, The Immunopathobiology of Syphilis: The Manifestations and Course of Syphilis Are Determined by the Level of Delayed-Type Hypersensitivity. The American Journal of Dermatopathology 2011.   Aronson IK and Soltani K, The enigma of the pathogenesis of the Jarisch-Herxheimer reaction. The British Journal of Venereal Diseases, 1976   Sellato TJ et al, The Cutaneous Response in Humans to Treponema pallidum Lipoprotein Analogues Involves Cellular Elements of Both Innate and Adaptive Immunity, The Journal of Immunology 2001   Spiller HA, Rethinking mercury: the role of selenium in the pathophysiology of mercury toxicity. Clinical Toxicology 2017   Sell S et al, Reinfection of chancre-immune rabbits with Treponema pallidum. I. Light and immunofluorescence studies. The American journal of pathology 1985.    Grant SS and Hung DT, Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response, Virulence 2013   Lant AF, Modern diuretics and the kidney. Journal of Clinical Pathology, 1981   Kamath SU et al, Mercury-based traditional herbo-metallic preparations: a toxicological perspective, Archives of Toxicology 2012.   Yeter et al, Mercury Promotes Catecholamines Which Potentiate Mercurial Autoimmunity and Vasodilation: Implications for Inositol 1,4,5-Triphosphate 3-Kinase C Susceptibility in Kawasaki Syndrome. Korean Circulation Journal 2013   Wöβmann W et al, Mercury intoxication presenting with hypertension and tachycardia. Archives of Disease in Childhood, 1999   Giacani L et al, Identification of the Treponema pallidum subsp. pallidum TP0092 (RpoE) Regulon and Its Implications for Pathogen Persistence in the Host and Syphilis Pathogenesis. Journal of Bacteriology 2013.   Edwards AM, From tooth to hoof: treponemes in tissue‐destructive diseases. Journal of Applied Microbiology, 2003   Wolgemuth CW, Flagellar motility of the pathogenic spirochetes. Seminars in Cell & Developmental Biology 2015.   Solomon HC and Kopp I, Fever Therapy. The New England Journal of Medicine 1937.   Rice KM et al, Environmental Mercury and Its Toxic Effects. Journal of Preventive Medicine and Public Health 2014.   Drusin LM, Electron microscopy of Treponema pallidum occurring in a human primary lesion. Journal of bacteriology 1969.   McNeely MC et al, Cutaneous secondary syphilis: Preliminary immunohistopathologic support for a role for immune complexes in lesion pathogenesis. Journal of the American Academy of Dermatology 1986.   Borenstein LA et al, Contribution of rabbit leukocyte defensins to the host response in experimental syphilis. Infection and immunity 1991.   Cabot RC et al, Case 51-1976 — Bicentennial CPC — Syphilis, Diarrhea and Death in the 1820's. The New England Journal of Medicine 1976.   Hobman JL and Crossman LC, Bacterial antimicrobial metal ion resistance. Journal of Medical Microbiology 2015   Gelpi A and Tucker JD, After Venus, mercury: syphilis treatment in the UK before Salvarsan. Sexually Transmitted Infections 2015.   MacHaffie et al, A study of the effectiveness of mercurial diuretics in treatment of cardiac decompensation. The American Journal of Cardiology 1958   Aberer W et al, Ammoniated mercury ointment: outdated but still in use. Contact Dermatitis 1990   Farhi D, Dupin N, Origins of syphilis and management in the immunocompetent patient: Facts and controversies. Clinics in Dermatology (2010) 28, 533–538   Frith J, “Syphilis – Its early history and Treatment until Penicillin and the Debate on its Origins,” Journal of Military and Veterans’ Health, 20(4), retrieved online at: http://jmvh.org/article/syphilis-its-early-history-and-treatment-until-penicillin-and-the-debate-on-its-origins/   Howes OD et al, “Julius Wagner-Jauregg, 1857-1940,” American Journal of Psychiatry, April 2009 Volume 166 Number 4, Volume 166, Issue 4, April, 2009, pp. 409-409.   Karamanou M et al, “Julius Wagner-Jauregg (1857-1940): Introducing fever therapy in the treatment of neurosyphilis.” Psychiatriki. 2013 Jul-Sep;24(3):208-12.   Simpson WM, “Artificial fever therapy of syphilis,” JAMA. 1935;105(26):2132-2140.   Tsay CJ, “Julius Wagner-Jauregg and the Legacy of Malarial Therapy for the Treatment of General Paresis of the Insane,” Yale J Biol Med. 2013;86(2): 245–254   Wagner-Jauregg J, “The history of malaria treatment of general paralysis.” Am J Psychiatry. 1946;02: 577-582   Shafer JK et al, Untreated syphilis in the male Negro: A prospective study of the effect on life expectancy. Public Health Rep. 1954 Jul; 69(7): 684–690.   Abara WE et al, Syphilis Trends among Men Who Have Sex with Men in the United States and Western Europe: A Systematic Review of Trend Studies Published between 2004 and 2015. PLoS One. 2016; 11(7): e0159309.   Nutton V, The Reception of Fracastoro's Theory of Contagion: The Seed That Fell among Thorns? Osiris, Vol. 6, Renaissance Medical Learning: Evolution of a Tradition (1990)   Tsaraklis A, Preventing syphilis in the 16th century: the distinguished Italian anatomist Gabriele Falloppio (1523-1562)  and the invention of the condom. Le Infezioni in Medicina, n. 4, 395-398, 2017.

This week Dick Fetti reviews: "Gateways to Annihilation" by death metal legends, Morbid Angel; "Syndrome/Antidrome", the latest album by German industrial duo Ke/Hil; and the legendary "Venereology" by the godfather of Japanese noise, MERZBOW. Then Ben the Beardo recommends Capcom's "Devil May Cry" remaster for the PS4. Disco Box Recommendations: Morbid Angel - Gateways to Annihilation CD/LP - Earache 2000 Ke/Hil - Syndrome/Antidrome LP - Tesco Org. 2017 MERZBOW - Venereology CD/2xLP - Release Entertainment/Relapse Records 1994/2019

Only a month in, and doing Venereology already? We must be crazy. Mike and Greh talk to dream guest Phil Blankenship (of The Cherry Point, LHD and the legendary Troniks label) about a record that changed his life (and his high school yearbook photo).

De quelles maladies peut souffrir le Père Noël et quels risques prend-il pour sa santé? Dans un article publié dans le "Journal of the European Academy of Dermatology and Venereology", deux médecins français se sont penchés sur l'état de santé de ce patient un peu particulier.

De quelles maladies peut souffrir le Père Noël et quels risques prend-il pour sa santé? Dans un article publié dans le "Journal of the European Academy of Dermatology and Venereology", deux médecins français se sont penchés sur l'état de santé de ce patient un peu particulier.

Speaker Anne Hanley (University of Cambridge) Title Venereology at the Polyclinic – Postgraduate study among general practitioners in England, 1899-1914 Event Paper given at the symposium, ‘Medical training, student experience and the transmission of knowledge, c.1800-2014’, organised by Laura Kelly, at CHOMI, UCD, October 2014 Summary In 1899, the British Medical Journal enthusiastically announced that a […] The post Venereology at the Polyclinic: Postgraduate Study Among GPs in England 1899-1914 appeared first on CHOMI MEDIA.